Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older, of any sex
• People who have been diagnosed with multiple myeloma (a type of blood cancer) according to established medical guidelines, and whose cancer has come back or stopped responding to their most recent treatment
• People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard health scoring system called the ECOG scale (scores 0 to 2, meaning fully active to capable of self-care)
• People whose blood counts, kidney function, and liver function meet the required levels
• People who are willing to use highly effective contraception with all sexual partners if they are sexually active

Who may not be able to join:

• People who have received an experimental treatment, chemotherapy, immunotherapy, or another anticancer treatment from a previous clinical study within 14 days or 5 half-lives before the first dose, whichever is the shorter period; or who have received any antibody-based cancer therapy within 30 days
• People who have previously been treated with a specific class of drugs called p300/CBP bromodomain inhibitors (confirm with trial site)
• People with known or suspected serious allergies to any ingredients in the study medications — inobrodib, pomalidomide, or dexamethasone — or to similar drugs used in the past, such as lenalidomide or thalidomide
• People taking medications, herbal supplements, or consuming foods that could interfere with how the study drugs work in the body (for example, strong CYP3A4 inducers or inhibitors — confirm with trial site)
• People who have had major surgery within 4 weeks before the first dose of the study treatment
• People who have received a live vaccine within 4 weeks before starting the study treatment
• People who still have active or unresolved side effects from previous treatments
• People who have had another active cancer (other than multiple myeloma) that was progressing or required a change in treatment within the last 24 months
• People who are pregnant or breastfeeding at any point during the study
• People with any other illness or medical history that could affect safety, the ability to follow the study requirements, or the ability for researchers to interpret the study results

Important: Always verify eligibility with the trial site directly before applying.